C4 Therapeutics, Inc.

C4 Therapeutics, Inc.verified

CCCC

Price:

$6.86

Market Cap:

$470.60M

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X muta...[Read more]

Industry

Biotechnology

IPO Date

2020-10-02

Stock Exchange

NASDAQ

Ticker

CCCC

The PE Ratio as of April 2024 (TTM) for C4 Therapeutics, Inc. (CCCC) is -2.57

According to C4 Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.57. This represents a change of 105.55% compared to the average of -1.25 of the last 4 quarters.

C4 Therapeutics, Inc. (CCCC) Historical PE Ratio (quarterly & annually)

How has CCCC PE Ratio performed in the past?

The mean historical PE Ratio of C4 Therapeutics, Inc. over the last ten years is -16.54. The current -2.57 PE Ratio has changed 1.45% with respect to the historical average. Over the past ten years (40 quarters), CCCC's PE Ratio was at its highest in in the September 2023 quarter at -0.85. The PE Ratio was at its lowest in in the December 2021 quarter at -24.93.

Quarterly (TTM)
Annual

Average

-16.54

Median

-19.37

Minimum

-32.13

Maximum

-2.12

C4 Therapeutics, Inc. (CCCC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of C4 Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 33.93%

Maximum Annual PE Ratio = -2.12

Minimum Annual Increase = -86.77%

Minimum Annual PE Ratio = -32.13

Quarterly (TTM)
Annual
YearPE RatioChange
2023-2.12-7.11%
2022-2.28-86.77%
2021-17.23-19.87%
2020-21.51-33.07%
2019-32.1333.93%

C4 Therapeutics, Inc. (CCCC) Average PE Ratio

How has CCCC PE Ratio performed in the past?

The current PE Ratio of C4 Therapeutics, Inc. (CCCC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-7.21

5-year avg

-15.05

10-year avg

-16.54

C4 Therapeutics, Inc. (CCCC) PE Ratio vs. Peers

How is CCCC’s PE Ratio compared to its peers?

C4 Therapeutics, Inc.’s PE Ratio is greater than Shattuck Labs, Inc. (-4.63), greater than Eliem Therapeutics, Inc. (-3.16), less than Prelude Therapeutics Incorporated (-1.76), less than Monte Rosa Therapeutics, Inc. (-2.35), less than Foghorn Therapeutics Inc. (-2.17), greater than Cyteir Therapeutics, Inc. (-3.52), greater than Rezolute, Inc. (-3.20), less than Century Therapeutics, Inc. (-1.34), greater than Edgewise Therapeutics, Inc. (-10.06), greater than Mineralys Therapeutics, Inc. (-6.21), greater than Cullinan Oncology, Inc. (-4.37), greater than Arvinas, Inc. (-5.82), greater than Nurix Therapeutics, Inc. (-5.24), greater than Kymera Therapeutics, Inc. (-14.10), greater than Revolution Medicines, Inc. (-12.05),

Build a custom stock screener for C4 Therapeutics, Inc. (CCCC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like C4 Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

C4 Therapeutics, Inc. (CCCC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like C4 Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is C4 Therapeutics, Inc.'s PE Ratio?

How is the PE Ratio calculated for C4 Therapeutics, Inc. (CCCC)?

What is the highest PE Ratio for C4 Therapeutics, Inc. (CCCC)?

What is the 3-year average PE Ratio for C4 Therapeutics, Inc. (CCCC)?

What is the 5-year average PE Ratio for C4 Therapeutics, Inc. (CCCC)?

How does the current PE Ratio for C4 Therapeutics, Inc. (CCCC) compare to its historical average?